| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fdaffe64e0056ceff97698a913ed913 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18832 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate |
2003-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff142631b6b8fb24481df59bdb55c235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44a1d138e7014d14e79991efdf285f31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e986f556ef6126034d39bedd382118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f8e7f945203c29f1765a3a065912c00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a25092e4d74379b777d44b4a7bcf8f |
| publicationDate |
2005-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005250718-A1 |
| titleOfInvention |
Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity |
| abstract |
The present invention provides pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity. By attaching a compound to a minus-strand RNA virus envelope protein having hemagglutinating activity, a pharmaceutical- or gene-carrier composition with lower hemagglutinating activity than a composition to which the compound has not been attached can be successfully constructed. For example, an embodiment of the present invention provides a viral vector whose erythrocyte agglutination activity and hemolytic activity are significantly lowered, and whose stability in blood is remarkably elevated. The pharmaceutical- or gene-carrier compositions provided in this invention can be preferably used for transferring pharmaceuticals or genes in vivo. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007105208-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009162320-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8691212-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10017784-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011223148-A1 |
| priorityDate |
2002-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |